1. MAPK/ERK Pathway
  2. Raf


Raf kinases are a family of three serine/threonine-specific protein kinases that are related to retroviral oncogenes. RAF is an acronym for Rapidly Accelerated Fibrosarcoma. Raf kinases participate in the RAS-RAF-MEK-ERK signal transduction cascade, also referred to as the mitogen-activated protein kinase (MAPK) cascade. Activation of RAF kinases requires interaction with RAS-GTPases. The three RAF kinase family members are: A-Raf, B-Raf, C-Raf (Raf-1). The B-Raf protein is involved in sending signals inside cells, which are involved in directing cell growth. It was shown to be faulty (mutated) in some human cancers. C-RAF or even Raf-1 is an enzyme that in humans is encoded by the RAF1 gene. The c-Raf protein is part of the ERK1/2 pathway as a MAP kinase kinase kinase (MAP3K) that functions downstream of the Ras subfamily of membrane associated GTPases. C-Raf is a member of the Raf kinase family of serine/threonine-specific protein kinases, from the TKL (Tyrosine-kinase-like) group of kinases.

Raf Related Products (33):

Cat. No. Product Name Effect Purity
  • HY-10201
    Sorafenib Inhibitor 99.83%
    Sorafenib is a potent multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
  • HY-12057
    Vemurafenib Inhibitor 99.53%
    Vemurafenib is a novel and potent inhibitor of B-RAF kinase, with IC50 values of RAFV600E (31 nM) and c-RAF-1 (48 nM).
  • HY-10201A
    Sorafenib Tosylate Inhibitor 99.73%
    Sorafenib tosylate is a potent multikinase inhibitor, with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
  • HY-14660
    Dabrafenib Inhibitor 98.96%
    Dabrafenib is an ATP-competitive inhibitor of BRAF with IC50s of 5 nM and 0.6 nM for CRAF and BRAFV600E, respectively.
  • HY-18972
    PLX8394 Inhibitor 98.44%
    PLX8394 is a potent and selective inhibitor of B-RafV600E (IC50~5 nM).
  • HY-101963
    AD80 Inhibitor 99.46%
    AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.
  • HY-15605
    LGX818 Inhibitor 99.88%
    LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
  • HY-10320
    Doramapimod Inhibitor 99.40%
    Doramapimod is a highly potent p38α inhibitor with an IC50 of 4 nM, also inhibits B-Raf with an IC50 of 83 nM and Abl with an IC50 of 14.6 μM.
  • HY-51424
    PLX-4720 Inhibitor 99.62%
    PLX 4720 is a potent and selective inhibitor of B-RafV600E(IC50=13 nM) and c-Raf-1Y340D/Y341D(IC50=6.7 nM); 10-fold selectivity for B-RafV600E than wild-type B-Raf.
  • HY-14660A
    Dabrafenib Mesylate Inhibitor 99.78%
    Dabrafenib (Mesylate) is a novel, potent, and selective Raf kinase inhibitor, and inhibits the kinase activity of B-RafV600Eand c-Raf with IC50 values of 0.6 and 5.0 nM, respectively.
  • HY-12558
    LY3009120 Inhibitor 99.72%
    LY3009120 is a small molecule that has been shown in vitro to be a pan-RAF inhibitor of all isoforms, blocking proliferation in both BRAF and RAS mutant cells.
  • HY-18997
    PLX7904 Inhibitor 98.15%
    PLX7904 is a potent and selective BRAF inhibitor, with IC50 of appr 5 nM against BRAFV600E in mutant RAS expressing cells.
  • HY-10542
    GW 5074 Inhibitor 98.77%
    GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC50 = 9 nM); displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms.
  • HY-11004
    AZ 628 Inhibitor 99.56%
    AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc.
  • HY-15246
    MLN 2480 Inhibitor 98.41%
    MLN 2480 is an orally active and selective inhibitor of pan-Raf kinase.
  • HY-18652
    Ro 5126766 Inhibitor >98.0%
    Ro 5126766 (CH5126766) is a potent and selective dual RAF/MEK inhibitor. For SK-MEL-28, SK-MEL-2, MIAPaCa-2, and SW480 cell lines, the IC50 is determined by WST-8 assay is 65, 28, 40, and 46 nM, respectively.
  • HY-12291
    HG6-64-1 Inhibitor 99.05%
    HG6-64-1 is a potent and selective B-Raf and mutant B-Raf inhibitor; more information can be found in Patent WO 2011090738.
  • HY-100510
    RAF709 Inhibitor 99.55%
    RAF709 is a novel Raf kinase inhibitor extracted from patent WO2014151616A1, compound example 131, has an IC50 of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively.
  • HY-50864
    GDC-0879 Inhibitor 99.70%
    GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well; no inhibition known to other protein kinases.
  • HY-15767
    TAK-632 Inhibitor 98.87%
    TAK-632 is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAFV600E, BRAFWT, respectively.